Bioelectronic Medicine: Targeting Inflammatory Disease with Electricity

We presented positive initial results in Crohn’s disease at the 2016 United European Gastroenterology meeting: six of the eight patients had seen a substantial reduction in their disease activity index scores, and three were in remission from the disease. As SetPoint looks ahead, several chronic disease areas are emerging as key bioelectronic medicine therapy targets, and our company is exploring a number of these. One of our preclinical programs explores bioelectronic medicine’s potential role as a treatment for MS.   New Target: Multiple Sclerosis In late 2017, SetPoint presented positive data from a study exploring the therapeutic effects of a bioelectronic medicine approach for MS at the European Committee and Americas Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS-ACTRIMS). Data showed that SetPoint’s therapy reduced demyelination and, more importantly, accelerated remyelination, which is a significant challenge in treating MS with currently available drugs/biologics. The study also demonstrated this approach reduced leakage of the blood-spinal cord barrier, which can prevent immune cell infiltration and further reduce disease progression. Current approved treatments for MS target the overactive immune response but do not repair damage to the myelin sheath – a critical aspect. These results show promise for a possible bioelectronic treatment for MS and lay the groundwork for further studies.   Bioelectronic Medicine Device: H...
Source: Mass Device - Category: Medical Devices Authors: Tags: Bioelectronic Medicine Clinical Trials Neuromodulation/Neurostimulation SetPoint Medical Sponsored Content Source Type: news